Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.56 |
| ▸ | TACR1 | P25103 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955434 | 0.88 | TACR1 (0.57) | DPP3TACR1OPRM1 | |
| SCHEMBL21954050 | 0.86 | CCKBR (0.60) | OPRM1 | |
| SCHEMBL23381319 | 0.83 | TACR1 (0.55) | DPP3TACR1PSMB9OPRM1 | |
| SCHEMBL26211725 | 0.83 | TACR1 (0.55) | DPP3TACR1PSMB9OPRM1 | |
| SCHEMBL23381127 | 0.82 | TACR1 (0.54) | DPP3TACR1PSMB9OPRM1 | |
| SCHEMBL29547724 | 0.82 | OPRM1 (0.55) | OPRM1 | |
| SCHEMBL29461794 | 0.81 | TACR1 (0.56) | DPP3TACR1OPRM1 | |
| SCHEMBL23381025 | 0.79 | OPRM1 (0.56) | DPP3TACR1OPRM1 | |
| SCHEMBL17268807 | 0.78 | DPP3 (0.63) | DPP3 | |
| SCHEMBL30921658 | 0.78 | ITGB2 (0.65) | DPP3TACR1MEN1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | DPP3 83/4885TACR1 138/4885KDM4E 4848/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP3 83/4885TACR1 138/4885KDM4E 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.